DOI: 10.1128/AAC.02155-18
Article Information
PubMed
Published By
History
- Received October 11, 2018
- Returned for modification December 20, 2018
- Accepted February 1, 2019
- Published online April 25, 2019.
Copyright & Usage
Copyright © 2019 American Society for Microbiology. All Rights Reserved.
Article Versions
- Accepted Manuscript version (February 19, 2019).
- You are viewing the most recent version of this article.
Author Information
- Jian Xua,
- Bin Wanga,
- Lei Fua,
- Hui Zhua,
- Shaochen Guoa,
- Haihong Huangb,
- Dali Yinb,
- Ye Zhanga and
- Yu Lua
- aBeijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute, and Beijing Chest Hospital, Capital Medical University, Beijing, China
- bBeijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China
- Address correspondence to Yu Lu, luyu4876{at}hotmail.com.
J.X. and B.W. contributed equally to the work.
Citation Xu J, Wang B, Fu L, Zhu H, Guo S, Huang H, Yin D, Zhang Y, Lu Y. 2019. In vitro and in vivo activities of the riminophenazine TBI-166 against Mycobacterium tuberculosis. Antimicrob Agents Chemother 63:e02155-18. https://doi.org/10.1128/AAC.02155-18.
